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A B S T R A C T
Angiogenesis, the growth and proliferation of new blood vessels, is important in a variety of pathophysiological pro-
cesses. However the role of angiogenesis in allergic rhinitis has not been well studied. Hence, the aim of this study was to
compare the vascularisation of the nasal mucous membrane of non-allergic, non-treated allergic and allergic patients
treated with mometasone furoate. A small piece of the nasal mucous membrane was taken from the frontal pole of the
lower nasal shell from 90 patients. The patients were divided in three groups, each containing 30 patients. First group of
patients (GP1) had a negative inhalatory allergen test, patients in second group (GP2) had positive test but were not un-
der treatment and the third group of patients (GP3) had positive results with the same test and were treated with mome-
tasone furoate for 15 days before analysis. Immunhistochemical staining with anti-CD31 and VEGF-C was performed.
Vascular phase was determined by using length density. Differences in expression of CD31 and VEGF-C were compared
using one-way ANOVA and Tukey HSD post-hoc tests. Significantly lower values of CD31 and VEGF-C expression were
observed in GP1 in compare with GP2 and GP3 (p<0.001, p=0.013, respectively). In GP3 the microvessel density was
significantly lower than in GP2 (p<0.001), but higher than in GP1. Our results demonstrated that 15-day treatment
with mometasone furoate results in a significant reduction of the density of vascular parameters in allergic patients.
Key words: vascularisation, nasal mucous membrane, allergy, mometasone furoate
Introduction
Allergy represents an inappropriate response of our
immunological system to various factors from our sur-
roundings1–3. Allergic rhinitis affects 10–40% of the po-
pulation4. It is provoked by inflammatory reactions me-
diated through immunoglobulin E after exposure to the
allergen. Angiogenesis has an important role in various
pathological mechanisms5–7. It is supposed that the vas-
cularisation in nasal mucous membrane differs from that
in the healthy person. Augmentation of the number of
blood vessels, which could be expected in allergic pa-
tients, may be one of the factors that significantly affects
total augmentation of vasculature surface, with conse-
quently greater number of eosinophiles and other in-
flammatory cells penetrating into the surrounding tis-
sues8,9. The greater the number of blood vessels, the
greater permeability and subsequent inflammatory reac-
tion are. The aim of this study is to prove whether the
blockage of allergic reaction and, in consequence, the re-
duction in vascularisation of the nasal mucous mem-
brane would follow topic application of mometasone




The small piece of the nasal mucous membrane speci-
mens, taken from the frontal pole of the lower nasal
shell, analyzed in this study were obtained from a total of
90 patients. After allergy tests to inhalatory allergens in-
cluding grass, weed, tree pollen, feathers, herbal fibbers,
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fungi, fabric, animal hair, domestic dust, Dermatopha-
goides pteronyssimus and bacteria, the patients were di-
vided into three groups, each group included 30 patients.
The first group (GP1) consisted of patients without aller-
gies and with negative allergic reaction to all allergens,
and it included 15 female and 15 male patients, with age
range from 19–58 years (median 35 years). The second
group (GP2) consisted of allergic patients with positive
allergic reaction to one or more allergens; it included 12
female and 18 male patients, with age range from 20–64
years (median 35 years). The third group consisted of al-
lergic patients treated with mometasone furoate, and it
included 14 female and 16 male patients, with age range
from 18–65 years (median 33 years). The patients in-
cluded in this study voluntarily participated and all have
signed the informed consent agreement before investiga-
tion started. Also, the study has been approved by The
Ethics Committee, of the School of Medicine, University
of Rijeka, Croatia.
Immunohistochemistry and vascular density
analysis
A small piece of the nasal mucous membrane, mea-
suring 5x5 mm, was excised from the lower nasal shell,
formalin fixed and embedded in paraffin. A 4µm thick
sections were cut and immunohistochemically examined
for the expression of CD31 (1:50, clone JC 70A, DA-
KOA/S, Glostrup, DK) and VEGF-C (1:100, clone F 8/86,
DAKO)10–13. The vascular phase of the nasal mucous
membrane was determined by the stereological method
using the length density variable. Length density is a rel-
ative stereological variable that gives us the length of a
certain curve in a unit of volume. The property of length
density has an exponent of –2 (cm1/cm3=cm–2 – our re-
search made use of mm–2). The trace of a one-dimen-
sional curve in a plane is a dimensionless value called a
transection point, marked Q. Its density in the test plane
is referred to as density transection (QA). The formula
used to calculate the length density was Lnf=2xQt/At);
where Qt stands for the number of transections, and At
for the test plane surface, which in our case equals 0.013
mm2. Approximately 100 measurements per specimen
were taken during the study and mean values were cal-
culated for each sample.
Statistical analysis
Statistical analysis was performed using Statistica 6.1
software (StatSoft, Inc., Tulsa, OK, USA). The distribu-
tion of data was tested for normality using Kolmogo-
rov-Smirnov test. The measures of central tendency for
continuous data such as CD31 and VEGF-C expression
were compared for differences between all three groups
by one-way ANOVA and Tukey HSD as a post-hoc test.
All statistical values were considered significant at the p
level of 0.05 or less.
Results
Immunohistochemical expression of CD31 and num-
ber of microvessels in all groups of patients are summa-
rized in Table 1. Statistical analysis revealed the signifi-
cant differences of microvessel density between all three
groups of patients (p<0.001). Significantly higher CD31
expression (microvessel density) was observed in GP2
group (allergic non-treated patients) in comparison to
other two GPs (p<0.001). In GP3 (treated allergic pa-
tients) the microvessel density was significantly lower
than in non-treated patients (p<0.001), but higher than
in GP1 group (control, non-allergic patients).
Table 2 shows values of VEGF-C expression and
lymph vessels density in all three GPs. Histologically
there was a significant decrease in the number of lymph
vessels in the allergic patients following mometasone
therapy (Figure 1). Significantly lower values of VEGF-C
expression was observed in GP1 group (non-allergic pa-
tients) (p<0.001). Increased levels of VEGF-C expression
and lymph vessels was observed in the GP3 (allergic
treated patients) when comparing with GP1 (p=0.013).
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TABLE 1
THE AVERAGE NUMBER AND DIFFERENCES OF BLOOD



















*Significant difference between all three groups
TABLE 2
THE AVERAGE NUMBER AND DIFFERENCES OF LYMPH



















*Significant difference between all three groups
Discussion
By definition allergic rhinitis is the most presented
chronic illness of the respiratory tract in the developed
countries. It is presented by abnormal inflammation of
nasal mucous membrane characterised by nasal obstruc-
tion, aqueous rhinorrhea, sneezing, nasal itching and
postnasal drip14,15. It is a prototype of IgE mediated ill-
ness that is manifested as a response to seasonal aller-
gens or permanent allergens and has the genetic com-
ponent15. Angiogenesis plays an important role in the
pathological mechanisms considering the facts that the
vascularisation of the nasal mucosa of the allergic pa-
tients differs from the nasal mucosa of healthy individu-
als. Mometasone furoate is a corticosteroid drug16. It
presents a powerful anti-inflammatory agent for reduc-
ing symptoms of seasonal and permanent allergic rhi-
nitis8,9,17. Mometasone furoate has minimal system activ-
ity and is very well tolerated by the patients. It affects
the nasal glucocorticoide receptors thus inhibits synthe-
sis and/or secretion of inflammatory mediators16. Mome-
tasone furoate inhibits leukotrien synthesis diminishing
blood vessels permeability18–20. In vitro experiments have
shown that mometasone furoate induces an inhibition of
pro-inflammatory Th2 cytokines16.
Conclusion
The intensity of the allergic reaction is, therefore,
proportional to the permeability of the blood vessels.
When is Mometasone furoate applied 15 days before the
surgical procedure, it inhibits interleukin release and re-
lease of other cytokines together with inhibition of the
synthesis of leukotriens. The consequence is a reduction
of vascular permeability and the reduction of the number
of blood vessels in the nasal mucous membrane. Thus, all
the results show that along with the permeability of the
blood vessels for the intensity of the allergic reaction, the
density of the blood vessels is of the same importance.
The results presented in this study have confirmed our
results from previous pilot study. We have shown that af-
ter a 15-day treatment with mometasone furoate nasal
mucous membrane of allergic patients shows significant
reduction of density of the vascular elements.
R E F E R E N C E S
1. TUR^I] P, LIPOZEN^I] J, MILAVEC-PURETI] V, MARINOVI]
KULI[I] S, Coll Antropol, 35 (2011) 83. — 2. MEHULI] M, MEHULI]
K, MALO^A VULJANKO I, KUKULJ S, POPOVI] GRLE S, DUGAC
VUKI] A, BARI[I] B, PLAVEC D, Coll Antropol, 35 (2011) 529. — 3.
JUKI] T, ABIDOV M, IHAN A, Coll Antropol, 35 (2011) 1219. — 4. MO-
RI S, FUJIEDA S, SUNAGA H, FOX SB, SAITO H, Clin Exp Allergy, 30
(2000) 1637. DOI: 10.1046/j.1365-2222.2000.00903.x. — 5. DOBRILA-
-DINTINJANA R, VANIS N, DINTINJANA M, RADI] M, Coll Antropol,
36 (2012) 1063. — 6. PIGAC B, DMITROVI] B, MARI] S, MASI] S, Coll
Antropol, 36 (2012) 227. — 7. JAKOVLJEVI] G, CULI] S, STEPAN J,
KOSUTA I, SEIWERTH S, Coll Antropol, 35 (2011) 1071. — 8. ONRUST
S, LAMB HM, Drugs, 56 (1998) 725. DOI: 10.2165/00003495-199856040
-00018. — 9. SCHENKEL E, Expert Opin Pharmacother, 4 (2003) 1579.
DOI: 10.1517/14656566.4.9.1579. — 10. NICHOLSON SA, MC DERMOTT
MB, DE YOUNG BR, SWANSON PE, Appl Imunohistochem Mol Mor-
phol, 8 (2000) 19. — 11. JOUKOV V, PAJUSOLA K, KAIPAINEN A, CHI-
LOV D, LAHTINEN I, KUKK E, SAKSELA O, KALKKINEN N, ALI-
TALO K, EMBO J, 15 (1996) 290. — 12. BERSE B, BROWN LF, VAN DE
WATER L, DVORAK HF, SENGER DR, Mol Biol Cell, 3 (1992) 211. — 13.
ZAMOLO G, GRUBER F, CABRIJAN L, MICOVI] V, ITERNICKA Z, JO-
NJI] N, Acta Med Okayama, 55 (2001) 289. — 14. LÜNDBACK B, Clin
Exp Allergy, 28 (1998) 3. — 15. BOUSQUET J, VAN CAUWENBERGE P,
KHALTAEV N, J Allergy Clin Immunol, 108 (2001) 147. DOI: 10.1067/
mai.2001.118891. — 16. FRIERI M, THERATTIL J, CHAVARRIA V, CO-
SACHOV J, KUMAR NS, WANG SF, SANSONE G, ETZEL J, DELLE-
VECCHIA D, ZITT M, MESARINA-WICKI B, NOLOP KB, Ann Allergy
Asthma Immunol, 81 (1998) 431. DOI: 10.1016/S1081-1206(10)63141-9.
— 17. AUSTIN RJ, MASCHERA B, WALKER A, FAIRBAIRN L, MEL-
DRUM E, FARROW SN, UINGS IJ, Eur Respir J, 20 (2002) 1386. DOI:
10.1183/09031936.02.02472001. — 18. BERKOWITZ RB, BERNSTEIN
DI, LAFORCE C, PEDINOFF AJ, ROOKLIN AR, DAMARAJU CR, ME-
SARINA-WICKI B, NOLOP KB, Allergy, 54 (1999) 64. DOI: 10.1034/j.
1398-9995.1999.00713.x. — 19. SPECTOR SL, Ann Allergy Asthma Im-
munol, 75 (1995) 463. — 20. BERLUCCHI M, PEDRUZZI B, Clinical Medi-
cine Insights, 2 (2010) 761.
M. Kujund`i} et al.: Mometasone Furoate and Nasal Vascularisation, Coll. Antropol. 37 (2013) 1: 127–130
129
Fig. 1. Immunohistochemical staining for VEGF-C. A) Mucosa
of patients with allergy shows oedema and high number of VEGF-
-C positive lymph capillaries. B) Histologically there was a sig-
nificant decrease of epithelial oedema and VEGF-C positivity (lymph
capillaries) in allergic patients following mometasone therapy.
Magnification 100x and 200x, respectively.
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VASKULARIZACIJA SLUZNICE NOSA U ALERGI^NIH BOLESNIKA LIJE^ENIH MOMETAZON
FUROATOM
S A @ E T A K
Angiogeneza, rast i proliferacija novih krvnih `ila, va`na je u razli~itim patofiziolo{kim procesima. Me|utim, uloga
angiogeneze u alergijskom rinitisu jo{ nije detaljno prou~ena. Stoga je cilj ove studije usporediti vaskularizaciju sluznice
nosa ne-alergi~ara, nelije~enih alergi~ara i alergi~nih bolesnika lije~enih mometazon furoatom. Mali komadi} sluznice
nosa uzet je s prednjeg dijela donje nosne {koljke 90 bolesnika. Pacijenti su podijeljeni u tri skupine, svaka s po 30
bolesnika. Prva skupina bolesnika (GP1) bila je negativna na inhalatorne alergene, bolesnici u drugoj skupini (GP2) bili
su pozitivni na inhalatorne alegrene, ali nisu lije~eni, a tre}u skupinu pacijenata (GP3) ~ine pacijenti s pozitivnim
testom na inhalatorne alergene koji su tijekom 15 dana prije uzimanja uzorka bili lije~eni mometazon furoatom. Pro-
vedeno je imunohistokemijsko bojenje anti-CD31 i VEGF-C. Vaskularna faza odre|ena je kori{tenjem du`inske gusto}e.
Razlike u ekspresiji CD31 i VEGF-C su komparirane kori{tenjem one-way ANOVA i Tukey HSD post-hoc testova. Zna-
~ajno ni`e vrijednosti CD31 i VEGF-C ekspresije dobivene su u GP1 u usporedbi s GP2 i GP3 (p<0,001, p=0,013,
slijedom). U skupini GP3 gusto}a krvnih `ila je zna~ajno ni`a nego u GP2 (p<0,001), ali vi{a nego u GP1. Dobiveni
rezultati pokazuju da 15-dnevni tretman mometazon furoatom rezultira zna~ajnim smanjenjem gusto}e krvnih `ila u
alergi~nih bolesnika.
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